Almost every compound filed under "metabolic" on a research-peptide shelf works by talking to a receptor. GLP-1 analogs engage GLP-1R. GHRH analogs engage GHRH-R. Even fragments with contested pharmacology are, at bottom, signaling molecules.
Adipotide is not that. It is a targeted cytotoxic — a short molecular address label chemically fused to a membrane-disrupting warhead, designed to find one cell population in the body and kill it. That architecture is the whole story. It explains the dramatic preclinical results, it explains the toxicology signal, and it explains why the compound's development record looks nothing like that of the incretins it sometimes sits beside in a catalog.
It also makes adipotide one of the most frequently mischaracterized research compounds.
A homing domain bolted to a warhead
The full chemical description, given verbatim in the 2011 primate study that popularized the name, is CKGGRAKDC-GG-(D)(KLAKLAK)₂. Read it as three parts.
CKGGRAKDC is the targeting domain — a nine-residue motif with cysteines at both ends, which form a disulfide bond that constrains the sequence into a small cyclic loop. This is the "address." It was not designed at a bench; it was fished out of a library by in vivo phage display, a selection method that injects billions of random peptide-displaying phage into an animal and recovers the ones that accumulate in a tissue of interest. Kolonin and colleagues reported the result in Nature Medicine in 2004 (10:625–632), identifying the motif as a homing sequence for the vasculature of white adipose tissue.
GG is a glycine-glycine spacer — a flexible hinge so the two functional halves don't sterically interfere.
(D)(KLAKLAK)₂ is the payload, and it predates adipotide entirely. This amphipathic sequence, built from D-amino acids for protease resistance, was introduced as a targeted proapoptotic module by Ellerby and colleagues in Nature Medicine in 1999 (5:1032–1038). Its useful property is conditional toxicity: it disrupts mitochondrial membranes, but it does not readily cross an intact plasma membrane on its own. Left in circulation it is comparatively inert. Delivered inside a cell, it triggers apoptosis. The homing domain supplies the delivery.
So adipotide is a modular chimera, not a hormone analog. Change the address and you get a different drug candidate aimed at a different tissue — which is precisely how the platform was designed to work.
Prohibitin: the address, and its day job
Kolonin's 2004 work identified prohibitin as the binding partner for the CKGGRAKDC motif, and reported it as enriched on the luminal surface of endothelial cells lining white adipose tissue vasculature. Prohibitin is an evolutionarily conserved, multifunctional protein best known as a scaffold in the inner mitochondrial membrane — its appearance on the endothelial cell surface is the unusual feature that made it usable as a vascular "zip code."
Framing matters here. Prohibitin was selected as a marker, not a signaling receptor being agonized. Adipotide does not activate a prohibitin pathway; it uses prohibitin as a docking point so the payload is internalized in the right neighborhood.
That said, later work from the same research lineage showed the address has a day job. Salameh and colleagues reported in JCI Insight (2016) that prohibitin and annexin A2 interact on adipose endothelium in a complex with the fatty-acid transporter CD36, and that disrupting that interaction impairs fatty acid transport into fat tissue. Follow-on work in Diabetes (2022) described endothelial prohibitin as mediating bidirectional long-chain fatty acid transport in white and brown adipose tissue.
This is an important nuance that vendor summaries usually flatten: prohibitin is not merely a passive label. It sits in machinery that moves fat. Whether any of adipotide's observed metabolic effects run through that machinery rather than through vascular ablation alone has never been cleanly resolved.
The monkey study that made the name
The landmark result is Barnhart et al., Science Translational Medicine, 9 November 2011 (3:108ra112) — a study in spontaneously obese Old World monkeys, conducted at MD Anderson.
The claims are specific. Adipotide administration "induced targeted apoptosis within blood vessels of white adipose tissue and resulted in rapid weight loss and improved insulin resistance." MRI and DXA imaging confirmed a marked reduction in white adipose tissue — not just scale weight, but body-composition evidence. In the main cohort (15 obese rhesus macaques, 10 treated and 5 controls, dosed daily for four weeks), the treated animals lost −7.4% to −14.7% of pretreatment body weight, against a −3.5% to +1.0% range in controls. The authors positioned the compound as "a prototype in a new class of candidate drugs."
The same abstract contains the finding that defines the compound's safety conversation: at the doses studied, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function. That is the authors' own characterization, in a primate model, and it is the origin of everything later written about adipotide and kidneys.
The paper did not go unchallenged. A published comment by Criscione in the same journal (2012; 4:131le2, with author reply) argued that the weight loss may instead reflect a direct effect of adipotide on food consumption rather than the proposed vascular-ablation mechanism. A reduced-intake confounder is a serious alternative explanation for any anti-obesity result, and the exchange remains part of the peer-reviewed record.
What the trial registry actually says
Adipotide reached humans exactly once, on paper. The technology was licensed from MD Anderson to Ablaris Therapeutics, a subsidiary formed by Arrowhead Research, while MD Anderson sponsored the clinical study.
NCT01262664 — "A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity" — is a dose-escalation safety study of a single 28-day cycle of daily subcutaneous administration. The registry record states:
- Start date: 24 May 2012
- Planned enrollment: up to 39 patients
- Actual enrollment: 4
- Overall status: TERMINATED
- Reason given: "Terminated per PI's request"
- Completion date: 2 January 2019
- Results posted: none
Over roughly six and a half years, the first-in-human study accrued four of a planned thirty-nine participants and closed without posting results. No human efficacy or safety data for adipotide has been published in the peer-reviewed literature or the registry.
This is where the compound's internet lore diverges from its record. The widely repeated claim that the program "ended because of kidney toxicity in humans" does not appear in the registry record, and no human trial report exists to support or refute it. The documented renal findings are the reversible proximal-tubule changes in the 2011 primate study. The accurate statement — and the more useful one for anyone assessing evidence maturity — is that the human safety question was never answered, because the trial that would have answered it enrolled four people and stopped.
How this differs from every other "fat-loss peptide" on the shelf
Two weeks ago this blog covered AOD-9604, whose story is almost the mirror image: a completed Phase IIb efficacy program with a clean safety record that simply failed to beat placebo on weight loss. Adipotide's record is the opposite shape — striking preclinical effect sizes, a real toxicology signal in primates, and a human program that produced essentially no data at all.
Both differ again from the approved incretins. Semaglutide and tirzepatide are receptor agonists studied in tens of thousands of trial participants. Adipotide is a cytotoxic agent with four documented human exposures and no published outcome. These are not adjacent points on one evidence spectrum — they are different universes of evidentiary maturity.
There's a mechanistic contrast too. Much of the tissue-repair literature concerns compounds studied for pro-angiogenic activity — building vasculature. Adipotide was designed to do the reverse in one tissue: ablate it. Selectivity is therefore the entire safety argument, and selectivity is what a homing peptide can only ever deliver imperfectly.
Where prohibitin targeting went next
The target did not die with the trial. In July 2025, Chan and colleagues in the Craik group at the University of Queensland published mixed-chirality prohibitin peptides in the Journal of the American Chemical Society (147:24628–24642), reporting a redesigned series aimed at white adipose tissue with improved stability. Their most potent analog, PTP-r, is described as prohibitin-TP01 substituted with D-arginine — sequence D-(RLARLAR)₂ replacing the classic warhead.
Two caveats are essential. First, these are new analogs, not adipotide, evaluated in a high-fat-diet mouse model. Second, the authors propose mitochondrial uncoupling as the mechanism for their compounds — a proposal specific to that series, not a retroactive revision of how adipotide itself is understood to act. What the paper establishes is that prohibitin-directed adipose targeting remains an active medicinal-chemistry problem, approached now through chirality and stability engineering rather than the original chimera.
Identity and QC: what analysis can and cannot confirm
Adipotide is unusually demanding to characterize, and this is where the quality conversation gets specific.
Chirality is invisible to mass spectrometry. D- and L-amino acids are isobaric — identical in mass. MS will confirm that a sample's mass matches D-(KLAKLAK)₂ while being completely blind to whether the payload was synthesized in the D-configuration. Since D-chirality is the entire basis for the payload's protease resistance, a mass match is not an identity confirmation here; resolving it requires chiral-specific analysis, which is not part of a routine COA panel. Our post on HPLC versus mass spectrometry covers what each technique does and does not see.
The disulfide state is a separate question. The CKGGRAKDC domain is designed as a cyclic loop closed by a disulfide bridge, and cyclic versus reduced linear forms differ by only two mass units — detectable with good instrumentation, easy to miss with sloppy work.
Two-domain chimeras fail in characteristic ways. A truncated product missing the payload has an obviously different mass and should be caught. A product with the right total mass but wrong assembly may not be. Longer sequences with mixed chirality and a spacer carry more process-related impurity risk than a simple linear peptide — a reason to read the actual chromatogram rather than a headline purity percentage.
FAQ
Is adipotide related to GLP-1 compounds? No. It shares no mechanism, no receptor and no structural lineage with incretin analogs. Adipotide is a targeted proapoptotic chimera; GLP-1 analogs are receptor agonists.
Does adipotide have any approved medical use? No. It has never been approved by any regulator, and the only registered human study was terminated with four participants enrolled and no results posted.
Why do so many sources say it failed due to human kidney toxicity? Because the primate paper reported reversible renal proximal-tubule changes, and that finding has been repeatedly restated as if it were a human trial outcome. The registry lists the termination reason as "per PI's request," and no human data was ever published — so the claim is unverifiable in either direction.
For mechanism-first context on other catalog compounds, see the research library.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.